Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Hematology ; 29(1): 2399430, 2024 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-39248713

RESUMO

BACKGROUND: Renal insufficiency (RI) is a key factor affecting the prognosis of multiple myeloma (MM) patients. Because the benefit of daratumumab for treating MM patients with RI remains unclear, our objective was to evaluate the efficacy of daratumumab on MM patients with RI. METHODS: We conducted a systematic search of the PubMed, EMBASE, and Cochrane Library databases as of October 24, 2023. Two independent reviewers screened the article titles, abstracts, and full text to identify the randomized controlled trials (RCTs) meeting the inclusion and exclusion criteria. Meta-analyses were performed using RevMan version 5.4. Outcomes of interest were progression-free survival (PFS), overall survival (OS), complete response or better (≥CR), and minimal residual disease (MRD) negativity, all calculated as hazard ratios (HRs) or risk ratios (RRs) with 95% confidence intervals (CIs). RESULTS: A total of 10 RCTs with 5003 patients were included. Add-on daratumumab improved PFS and OS among newly diagnosed MM (NDMM) patients with RI (HR 0.48 [95% CI: 0.36, 0.64, I2 = 65%] and HR 0.63 [95% CI: 0.48, 0.82, I2 = 0%]) as well as relapsed/refractory MM (RRMM)-RI patients, compared with the control group (HR 0.46 [95% CI: 0.37, 0.58, I2 = 0%] and HR 0.68 [95% CI: 0.51, 0.92, I2 = 0%]). In terms of the renal status, the efficacy of add-on daratumumab for MMRI patients was similar to that for MM patients with normal renal function. A prolonged PFS benefit for add-on daratumumab treatment versus the control was evident across all RRMM-RI subgroups, and the benefits tended to increase with the follow-up time. CONCLUSIONS: Our results indicate that MM patients with RI could benefit from a daratumumab-added regimen regardless of MM status. Additional high-quality RCTs are still warranted to confirm our findings.


Assuntos
Anticorpos Monoclonais , Mieloma Múltiplo , Insuficiência Renal , Mieloma Múltiplo/tratamento farmacológico , Mieloma Múltiplo/complicações , Mieloma Múltiplo/mortalidade , Humanos , Anticorpos Monoclonais/uso terapêutico , Insuficiência Renal/etiologia , Insuficiência Renal/tratamento farmacológico , Resultado do Tratamento
2.
Sci Total Environ ; 946: 174407, 2024 Oct 10.
Artigo em Inglês | MEDLINE | ID: mdl-38964416

RESUMO

Shale gas extraction in China often faces inadequate reservoir stimulation after initial fracturing of the wells, leading to production challenges despite abundant residual gas. Refracturing is an effective approach to enhance gas recovery; however, its impact on water consumption remains understudied. This study analyzes two refracturing techniques employed in China's largest shale production field, Fuling: temporary plugging and diverting refracturing (TPD) and wellbore reconstruction refracturing (WR), focusing on fracturing efficiency and water consumption. The results demonstrate that WR refracturing exhibits superior fracturing performance but consumes 1.3 times more water than initial fracturing. Considering 315 wells that required refracturing from 2013 to 2017, this study reveals, for the first time, that the lifecycle water consumption for shale gas production with refracturing is more than twice that without refracturing. The estimated total water consumption for the Fuling shale gas field over the next decade, incorporating refracturing, is approximately 7594.53 × 104 m3. By including the water consumption of refracturing, this study provides a more comprehensive evaluation of water usage throughout the entire lifecycle of shale gas development. The findings offer new insights for assessing water consumption in global shale gas development and highlight the importance of considering refracturing when evaluating the environmental impacts and resource management strategies associated with shale gas extraction.

3.
ACS Omega ; 9(15): 17626-17635, 2024 Apr 16.
Artigo em Inglês | MEDLINE | ID: mdl-38645375

RESUMO

Block H, located in western Hubei-eastern Chongqing, remains at a low exploration degree. Characterized by its complex structural attributes, the area presents adverse conditions such as a thin thickness of high-quality shale reservoir, rapid lateral formation occurrence, and poor stratigraphic correlation, challenging conventional geosteering methods. The primary shale gas reservoir in Block H corresponds to the Upper Permian Wujiaping Formation. To ensure that the shale gas horizontal wells in this block effectively penetrate high-quality gas reservoirs, this study delves into the geological characteristics of this stratigraphic unit, identifies principal challenges faced by current geosteering techniques, and introduces a tailored technical solution. This solution encompasses the application of real-time 3D geological modeling to track while drilling, identification of steering marker layers, optimization of steerable tools, and optimization of the steering trajectory while drilling. In the technology of optimization of the steering trajectory while drilling, a trajectory control calculation model based on the average angle technique was established for the first time. Additionally, a sectional control chart for marker layers and well inclination under different deflecting constraints was established. These methods have solved the problems of large error in target prediction and poor trajectory control effects by using the equal thickness method alone. The findings from this study can significantly enhance target prediction and trajectory control accuracy in complex structural areas, offering pivotal insights for the proficient development of analogous shale gas reservoirs in the future.

4.
Ann Hematol ; 103(1): 153-162, 2024 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-37749319

RESUMO

The purpose is to ascertain the clinical impact of Castleman disease (CD) by reassessment of the real-world data from Peking University First Hospital (PKUFH). The results will contribute to the standardization of diagnosis and treatment on CDs. Based on the last 15-year retrospective real-world data from Peking University First Hospital (PKUFH), we reclassified and re-evaluated the clinical and pathological information of patients with pathologically suspected diagnosis of CD. A total of 203 patients were included in our study, in which the diagnosis of CD was confirmed in 189 cases, including 118 patients with unicentric CD (UCD, n = 118, 62.4%) and 71 patients with multicentric CD (MCD, n = 71, 37.6%). A total of 44.1% (n = 52) of UCDs in our cohort were complicated with paraneoplastic pemphigus (PNP). The treatment of UCD is primarily surgical, with a 5-year overall survival (OS) of 88.1%. Patients with PNP had a poorer prognosis than those without PNP (82.9% (95% CI 123-178) vs 92.8% (95% CI 168-196), log-rank p = 0.041). The rate of concurrent systemic symptoms was 74.6% (n = 53), and renal involvement occurred in 49.3% (n = 35) MCD patients. The MCD treatments were mainly chemotherapy regimens, with a 5-year OS of 77.6% (95% CI, 143-213). Patients with UCD demonstrate a better overall prognosis than patients with MCD. But the prognosis of those complicated with PNP was poor. The differential diagnosis of MCD is extensive. MCD treatment in China is heterogeneous. The inaccessibility of anti-IL-6-targeted drugs in China may contribute to the poor prognosis for patients with MCD.A preprint has previously been published (Guo et al. 34).


Assuntos
Hiperplasia do Linfonodo Gigante , Humanos , Hiperplasia do Linfonodo Gigante/diagnóstico , Hiperplasia do Linfonodo Gigante/epidemiologia , Hiperplasia do Linfonodo Gigante/terapia , Estudos Retrospectivos , Pequim/epidemiologia , Prognóstico , China/epidemiologia
5.
Front Cardiovasc Med ; 9: 911333, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-35707125

RESUMO

Background: Coexisting primary aldosteronism (PA) and subclinical Cushing's syndrome (SCS) caused by bilateral adrenocortical adenomas have occasionally been reported. Precise diagnosis and treatment of the disease pose a challenge to clinicians due to its atypical clinical manifestations and laboratory findings. Case Summary: A 49-year-old woman was admitted to our hospital due to fatigue, increased nocturia and refractory hypertension. The patient had a history of severe left hydronephrosis 6 months prior. Laboratory examinations showed hypokalaemia (2.58 mmol/L) and high urine potassium (71 mmol/24 h). Adrenal computed tomography (CT) showed bilateral adrenal masses. Undetectable ACTH and unsuppressed plasma cortisol levels by dexamethasone indicated ACTH-independent Cushing's syndrome. Although the upright aldosterone-to-renin ratio (ARR) was 3.06 which did not exceed 3.7, elevated plasma aldosterone concentrations (PAC) with unsuppressed PAC after the captopril test still suggested PA. Adrenal venous sampling (AVS) without adrenocorticotropic hormone further revealed hypersecretion of aldosterone from the right side and no dominant side of cortisol secretion. A laparoscopic right adrenal tumor resection was performed. The pathological diagnosis was adrenocortical adenoma. After the operation, the supine and standing PAC were normalized; while the plasma cortisol levels postoperatively were still high and plasma renin was activated. The patient's postoperative serum potassium and 24-h urine potassium returned to normal without any pharmacological treatment. In addition, the patient's blood pressure was controlled normally with irbesartan alone. Conclusion: Patients with refractory hypertension should be screened for the cause of secondary hypertension. AVS should be performed in patients in which PA is highly suspected to determine whether there is the option of surgical treatment. Moreover, patients with PA should be screened for hypercortisolism, which can contribute to a proper understanding of the AVS result.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA